Clinical Trials Browser

Phase 3 × Recruiting × osimertinib × Clear all

NCT04181060 2026-05-18

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT06417814 2026-05-14

TROPION-Lung15

Phase 3 Recruiting

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT06486142 2026-05-14

ERIS

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06670196 2026-05-08

A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06350097 2026-05-06

TROPION-Lung14

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05624996 2026-05-04

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Phase 3 Recruiting

Lung Neoplasms

NCT06838273 2026-04-20

A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06970639 2026-02-12

A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases

Phase 3 Recruiting

NSCLC Patients With Brain Metastasis

NCT06829459 2025-04-08

A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs

Phase 3 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06735391 2024-12-16

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Phase 3 Recruiting

Locally Advanced or Metastatic Non-squamous NSCLC

NCT05382728 2024-01-30

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Phase 3 Recruiting

NSCLC